UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September 17~~November 7, 2018

OSIRIS THERAPEUTICS, INC.

(Exact ~~name~~Name of Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Maryland	001-32966	71-0881115
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction ofincorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)

7015 Albert Einstein Drive, Columbia, Maryland		21046
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (443) 545 - 1800

~~Check~~ Not the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):Applicable

o (Former ~~Written~~name ~~communications~~or ~~pursuant~~former toaddress, ~~Rule 425~~if ~~under~~changed ~~the~~since ~~Securities~~last ~~Act (17 CFR 230.425~~report)

o Check ~~Soliciting~~the ~~material~~appropriate ~~pursuant~~box tobelow ~~Rule~~if the Form ~~14a~~8-12K ~~under~~filing is intended to simultaneously satisfy the ~~Exchange~~filing ~~Act~~obligation ~~(17~~of ~~CFR~~the ~~240.14a-12)~~registrant under any of the following provisions:

o ☐ ~~Pre-commencement~~Written communications pursuant to Rule ~~14d-2(b)~~ 425 under the ~~Exchange~~Securities Act (17 CFR ~~240~~230.~~14d-2(b~~425))

o ☐ ~~Pre-commencement~~Soliciting ~~communications~~material pursuant to Rule ~~13e~~14a-~~4(c)~~ 12 under the Exchange Act (17 CFR 240.~~13e~~14a-~~4(c~~12))

~~Indicate~~ ☐ byPre-commencement ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933~~ 14d-2(~~§230.405 of this chapter~~b) ~~or Rule~~ ~~12b-2~~under of the ~~Securities~~ Exchange Act of(17 ~~1934~~CFR (§240.~~12b~~14d-2 ~~of this chapter~~(b).)

~~Emerging~~ ☐ Pre-commencement ~~growth~~communications ~~company~~pursuant oto Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

If Indicate ~~an emerging growth company, indicate~~ by check mark ifwhether the ~~registrant~~Registrant ~~has~~is ~~elected~~an ~~not~~emerging togrowth ~~use~~company ~~the~~as ~~extended~~defined ~~transition~~in ~~period~~Rule ~~for~~405 ~~complying~~of ~~with~~the ~~any~~Securities ~~new~~Act orof ~~revised~~1933 ~~financial~~(§230.405 ~~accounting~~of ~~standards~~this ~~provided~~chapter) ~~pursuant~~or toRule ~~Section 13(a)~~ 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 oof this chapter).

~~Item~~ Emerging ~~8.01.~~growth ~~Other~~company ~~Events.~~☐

On If ~~September 17,~~an ~~2018,~~emerging ~~Osiris~~growth ~~Therapeutics~~company, ~~Inc.~~ ~~(the~~indicate ~~“Company”)~~by ~~issued~~check amark ~~press~~if ~~release~~the ~~announcing~~Registrant ~~the~~has ~~launch~~elected ofnot ~~GrafixPL~~to ~~PRIME™,~~use the ~~Company’s~~extended ~~first~~transition ~~ambient~~period ~~temperature~~for ~~stable~~complying ~~placental~~with ~~membrane~~any ~~product,~~new ~~beginning~~or onrevised ~~October 1,~~financial ~~2018.~~accounting Astandards ~~copy~~provided ofpursuant ~~the~~to ~~Company’s~~Section ~~press~~13(a) ~~release~~of isthe ~~attached~~Exchange ~~hereto as Exhibit 99~~Act.~~1 and are incorporated herein by reference.~~ ☐

Item 92.0102. Results ~~Financial~~of ~~Statements~~Operations and ~~Exhibits.~~Financial Condition

On November 7, 2018, Osiris Therapeutics, Inc. (dthe “Company”) announced its financial results for the ~~Exhibits~~quarter ended September 30, 2018. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Press release, dated September 17, 2018, announcing the launch of GrafixPL PRIME™ on October 1, 2018

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

2 Item 9.01. Financial Statements and Exhibits

~~SIGNATURES~~ (d) Exhibits

~~Pursuant~~ExhibitNumber toDescription ~~the requirements~~ of ~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~Exhibit

	OSIRIS THERAPEUTICS, INC.
	By:	/s/ Jason Keefer
		Jason Keefer
		Interim President
		and Chief Executive Officer
Date: September 17, 2018

99.1Press Release issued by the Company on November 7, 2018

3 2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	OSIRIS THERAPEUTICS, INC.

Dated: November 7, 2018	By:	/s/ JOEL ROGERS
		Joel Rogers
		Chief Financial Officer

Filing Compare · OSIRIS THERAPEUTICS, INC.